CRME - Cardiome Pharma Corp.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.30
-0.04 (-1.71%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.34
Open2.33
Bid0.00 x 0
Ask0.00 x 0
Day's Range2.27 - 2.33
52 Week Range1.29 - 4.84
Volume53,638
Avg. Volume173,719
Market Cap76.317M
Beta-0.94
PE Ratio (TTM)N/A
EPS (TTM)-0.90
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.84
Trade prices are not sourced from all markets
  • CNW Group6 days ago

    Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess®

    Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess®

  • CNW Group11 days ago

    Cardiome Announces Fifteen Xydalba™ and Zevtera® Abstracts at ECCMID 2018

    Cardiome Announces Fifteen Xydalba™ and Zevtera® Abstracts at ECCMID 2018

  • Zacks Small Cap Research13 days ago

    CRME: Cipher to Get Canadian Assets

    Cardiome Pharma Corp. (CRME) issued a press release reporting 2017 full-year results on March 13, 2018, and filed its 2017 financial statements and management discussion & analysis on SEDAR three weeks later. During 2017, Cardiome advanced Xydalba in Europe with a commercial launch in several EU states.

  • CNW Group16 days ago

    Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds

    Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds

  • CNW Group21 days ago

    Cardiome Highlights Partner SteadyMed's Progress Towards Trevyent NDA Resubmission

    Cardiome Highlights Partner SteadyMed's Progress Towards Trevyent NDA Resubmission

  • CNW Group26 days ago

    Cardiome Announces Recent Insider Purchases

    Cardiome Announces Recent Insider Purchases

  • PR Newswire26 days ago

    Cardiome Announces Recent Insider Purchases

    NASDAQ:CRME  TSX:COM VANCOUVER , March 28, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) announces that Dr. William Hunter , President and CEO and Justin Renz , Chief Financial Officer, ...

  • ACCESSWIRElast month

    Cardiome Pharma Agrees to Sell Drug Portfolio, Analysts Target Price, Financial Review

    NEW YORK, NY / ACCESSWIRE / March 22, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...

  • PR Newswirelast month

    Health Canada Accepts Cardiome's Xydalba New Drug Submission and Grants Priority Review

    VANCOUVER, March 22, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, announced today that Health Canada has accepted its New Drug Submission (NDS) for review of Xydalba™ (dalbavancin hydrochloride) and granted Priority Review status to the application. Cardiome expects to receive an approval decision for Xydalba during the third quarter of 2018. Under the proposed strategic transaction between Cardiome and Cipher Pharmaceuticals Inc. announced earlier this week, upon the close of the transaction, Cipher would sublicense the commercial rights to Xydalba as part of the Canadian business portfolio proposed for acquisition. "Health Canada's acknowledgement regarding the completeness of the NDS submission for Xydalba and granting of Priority Review are important milestones for Cardiome," said Kiran Bhirangi, M.D., Vice President, Clinical Development and Medical Affairs.

  • CNW Grouplast month

    Health Canada Accepts Cardiome's Xydalba New Drug Submission and Grants Priority Review

    Health Canada Accepts Cardiome's Xydalba New Drug Submission and Grants Priority Review

  • ACCESSWIRElast month

    Blog Exposure - Cipher to Acquire Cardiome’s Canadian Business Portfolio for $25.5 Million in Cash

    Stock Monitor: Apricus Biosciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 22, 2018 / Active-Investors.com has just released a free research report on Cardiome Pharma Corp. (NASDAQ: CRME ...

  • Benzingalast month

    Canaccord: Cardiome Pharma's Sale Of Canadian Business 'A Highly Positive Catalyst' For Shares

    CARDIOME PHARMA CORP (NASDAQ: CRME ) announced Tuesday it has agreed to divest its Canadian business to Cipher Pharmaceuticals for the U.S. dollar equivalent of $19.7 million.  The Analyst Canaccord Genuity's ...

  • CNW Grouplast month

    Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome

    Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome

  • PR Newswirelast month

    Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome

    MISSISSAUGA, ON, and VANCOUVER, March 20, 2018 /PRNewswire/ - Cipher Pharmaceuticals Inc. (CPH.TO) and Cardiome Pharma Corp. (Nasdaq:CRME and TSX:COM), today announced their entry into a definitive arrangement agreement pursuant to which Cipher will acquire the Canadian business portfolio of Cardiome.  The proposed transaction will be completed pursuant to the acquisition by Cipher of all of the outstanding shares of Cardiome, following a restructuring of Cardiome pursuant to a statutory plan of arrangement under the Canada Business Corporations Act.  Pursuant to the arrangement, Cardiome shareholders will receive common shares, on a one-for-one ratio, of a newly created Canadian entity named Correvio Pharma Corp. that will apply for a substitution listing on the Nasdaq and TSX. Correvio will acquire and hold all of Cardiome's pre-transaction assets, excluding the Canadian business portfolio being acquired by Cipher under the arrangement.  The arrangement is described in further detail below.

  • Zacks Small Cap Researchlast month

    CRME: Cardiome’s 2017 Full Year Results

    Cardiome was involved in substantial activity during the prior twelve months, beginning with the recognition of sales for Zevtera/Mabelio, the launch of Xydalba in several new geographies, and the expansion of the reach of Brinavess.  China’s regulatory authority granted Aggrastat an additional indication and SteadyMed is on track for its new drug application (NDA) for Trevyent.  As we began 2018, Esmocard posted record months in both January and February. In September, Cardiome entered into an agreement with Basilea to commercialize ceftobiprole (Zevtera/Mabelio) in 34 European countries and Israel.  Following the transaction, revenues were recognized on Cardiome’s income statement and beginning January 1st, 2018 all of Basilea’s sales representatives were added to Cardiome’s sales force.  Management commentary noted that they were able to achieve historical peak sales levels of the drug in January and surpass that in February, suggesting that better days are still ahead.

  • Associated Presslast month

    Cardiome reports 4Q loss

    The Vancouver, British Columbia-based company said it had a loss of 24 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • CNW Grouplast month

    Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results

    Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results

  • PR Newswirelast month

    Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results

    VANCOUVER, March 13, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today reported financial results for its fourth quarter and year ended December 31, 2017 and commented on recent accomplishments and plans. Aspen Medical, who also markets Aggrastat in South Africa, is a wholly-owned subsidiary of Aspen Pharmacare (a division of the Aspen Group), the largest pharmaceutical company in Africa.

  • ACCESSWIRElast month

    Cardiome Pharma Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 13, 2018 / Cardiome Pharma Corp. (NASDAQ: CRME ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 13, 2018 at 4:30 PM Eastern Time. ...

  • CNW Group2 months ago

    Marapharm Ventures Inc. Appoints Corey Klassen as Vice President of Corporate Development, Hires CFO and Adds Additional Independent Director

    Marapharm Ventures Inc. Appoints Corey Klassen as Vice President of Corporate Development, Hires CFO and Adds Additional Independent Director

  • CNW Group2 months ago

    Cardiome to Hold Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 13

    Cardiome to Hold Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 13

  • PR Newswire2 months ago

    Cardiome to Hold Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 13

    NASDAQ:CRME TSX:COM VANCOUVER , March 6, 2018 /PRNewswire/ -   Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected ...

  • Cardiome Pharma Corp (TSE:COM): Is Breakeven Near?
    Simply Wall St.2 months ago

    Cardiome Pharma Corp (TSE:COM): Is Breakeven Near?

    Cardiome Pharma Corp’s (TSX:COM): Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. The company’sRead More...

  • Are Cardiome Pharma Corp’s (TSE:COM) Interest Costs Too High?
    Simply Wall St.2 months ago

    Are Cardiome Pharma Corp’s (TSE:COM) Interest Costs Too High?

    Investors are always looking for growth in small-cap stocks like Cardiome Pharma Corp (TSX:COM), with a market cap of CA$63.04M. However, an important fact which most ignore is: how financiallyRead More...

  • Best TSX Growth Stocks
    Simply Wall St.2 months ago

    Best TSX Growth Stocks

    Why invest in a stock whose growth outlook that lags behind the market? Investors looking for companies with extraordinary future prospects in terms of profitability and returns should look atRead More...